Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial | Journal of Clinical Oncology
Cancers | Free Full-Text | Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer
First‐line Gemcitabine plus Nab‐paclitaxel Progression‐Free Survival... | Download Scientific Diagram
Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer
Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer | Journal of Pancreatology
Subgroup analyses for progression-free survival with nab-paclitaxel... | Download Scientific Diagram
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States | Advances in Therapy
Metastasiertes Pankreaskarzinom: Überlebensvorteil durch Paclitaxel -Nanopartikel
Nab-paclitaxel Plus Gemcitabine and Cisplatin for BTC
Progression-free survival (a) and overall survival (b) with... | Download Scientific Diagram
Nab-Paclitaxel plus Gemcitabin erweist sich beim metastasierten...
Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study - ScienceDirect
Gemcitabine Plus Nab-paclitaxel As A Second-line Treatment, 56% OFF
Cancers | Free Full-Text | Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group
![PDF] Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9c7d29ebccc5e3fac1b7a68fa9515274ea592f76/8-Table2-1.png "PDF] Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. | Semantic Scholar")
PDF] Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. | Semantic Scholar
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01) | BMC Cancer | Full Text
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial - The Lancet Gastroenterology ...
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer | British Journal of Cancer
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma | Nature Communications
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology
